カテゴリ： GlobalData, アメリカ, 企業調査

X4 Pharmaceuticals Inc：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：X4 Pharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C11033
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：39
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
X4 Pharmaceuticals Inc (X4 Pharma) is a pharmaceutical company that develops novel therapeutics to treat cancer and rare diseases. The company’s lead drug candidate, X4P-001-LD, is in Phase 2/3 trial used for the treatment for patients with WHIM and other immunodeficiency disease. It also develops X4P-001, a CXCR4 inhibitor used for the treatment of melanoma, refractory clear cell renal cell carcinoma (ccRCC), and other solid tumor indications. X4 Pharma’s pre-clinical products include X4P-002, designed for the treatment of brain cancers including glioblastoma multiforme. X4 Pharma is headquartered in Cambridge, Massachusetts, the US.

X4 Pharmaceuticals Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
X4 Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
X4 Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
X4 Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
X4 Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
X4 Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
X4 Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
X4 Pharma Raises USD25.8 Million in Venture Financing 11
X4 Pharma Raises USD37.5 Million in Series A Financing Round 12
X4 Pharma Raises USD0.7 Million in Seed Financing Round 13
Partnerships 14
X4 Pharma Enters into Research Agreement with Yale University 14
Licensing Agreements 15
X4 Pharma Enters into Licensing Agreement with Sanofi 15
Equity Offering 16
X4 Pharma Spin Off from Sanofi 16
X4 Pharmaceuticals Inc – Key Competitors 17
X4 Pharmaceuticals Inc – Key Employees 18
X4 Pharmaceuticals Inc – Locations And Subsidiaries 19
Head Office 19
Recent Developments 20
Corporate Communications 20
Nov 05, 2018: X4 Pharmaceuticals appoints Gary J. Bridger, PhD, to board of directors 20
Jul 12, 2018: X4 Pharmaceuticals Appoints Michael Wyzga as Chair of Board of Directors 21
Jan 23, 2017: X4 Pharmaceuticals Appoints Dr. Sudha Parasuraman as Chief Medical Officer 22
Product News 23
11/16/2017: First Clinical Data for X4P-001-RD Demonstrating Preliminary Activity in Patients with WHIM Syndrome will be Presented at American Society for Hematology Annual Meeting 23
10/30/2017: Clinical Data for X4P-001-IO in Combination with Inlyta (Axitinib) Demonstrated Encouraging Overall Response Rates (Including a Complete Response) and Disease Control Rates in Patients with Clear Cell Renal Cell Carcinoma 24
08/31/2017: First Data from Combination of X4P-001-IO and Inlyta (axitinib) in Patients with Clear Cell Renal Cell Carcinoma Will Be Presented at the European Society of Medical Oncology 2017 Congress 25
05/25/2017: X4 Pharmaceuticals Announces Initiation of the Phase 2 Expansion of its Phase 1/2 Study of X4P-001 in Patients with Advanced Clear Cell Renal Cell Carcinoma 26
05/17/2018: X4 Pharmaceuticals to Present Clinical Data from Phase 2 Study of X4P-001-RD in WHIM Syndrome 27
05/16/2018: X4 Pharmaceuticals to Present Clinical Data from Phase 2 Expansion Study of Combination of X4P-001-IO and Inlyta (axitinib) in Patients with Clear Cell Renal Cell Carcinoma 28
05/08/2018: X4 Pharmaceuticals to Present Clinical Data from Pilot Study of Combination of X4P-001-IO and Opdivo (nivolumab) 29
04/16/2018: X4 Pharmaceuticals Presents Clinical Data Demonstrating Single Agent X4P-001-IO Enhances Tumor Immunity 30
01/30/2017: X4 Pharmaceuticals Announces Initiation of a Phase 2/3 Clinical Study of X4P-001-LD in Patients with WHIM Syndrome, a Rare Genetic Primary Immunodeficiency Disease 31
01/26/2017: X4 Pharmaceuticals Announces Initiation of Clinical Study of X4P-001 in Combination with Opdivo for Patients with Advanced Clear Cell Renal Cell 32
Clinical Trials 33
Mar 15, 2018: X4 Pharmaceuticals to Report Clinical Biomarker Data with X4P-001 at the Upcoming 2018 American Association for Cancer Research (AACR) Annual Meeting 33
Dec 11, 2017: First Clinical Data for X4P-001-RD Demonstrated Promising Activity in Patients with WHIM Syndrome, a Primary Immunodeficiency Disease 34
Nov 10, 2017: X4 Pharmaceuticals Presents Clinical Data Demonstrating Immune Activation Through CXCR4 Pathway with X4P-001-IO 35
Nov 03, 2017: First Clinical Data from Combination of X4P-001-IO and Keytruda (pembrolizumab) in Patients with Melanoma Will Be Presented at the Society for Immunotherapy of Cancer Annual Meeting 36
Oct 25, 2017: Updated Clinical Data from Combination of X4P-001-IO and Inlyta (axitinib) in Patients with Clear Cell Renal Cell Carcinoma Will Be Presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 37
Sep 11, 2017: Initial Clinical Trial Data for Combination of X4P-001-IO and Inlyta® (Axitinib) Demonstrate Encouraging Disease Control Rates and Durable Clinical Responses in Patients with Clear Cell Renal Cell Carcinoma 38
Appendix 39
Methodology 39
About GlobalData 39
Contact Us 39
Disclaimer 39

List of Tables
X4 Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts 2
X4 Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
X4 Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
X4 Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
X4 Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
X4 Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
X4 Pharma Raises USD25.8 Million in Venture Financing 11
X4 Pharma Raises USD37.5 Million in Series A Financing Round 12
X4 Pharma Raises USD0.7 Million in Seed Financing Round 13
X4 Pharma Enters into Research Agreement with Yale University 14
X4 Pharma Enters into Licensing Agreement with Sanofi 15
X4 Pharma Spin Off from Sanofi 16
X4 Pharmaceuticals Inc, Key Competitors 17
X4 Pharmaceuticals Inc, Key Employees 18

List of Figures
X4 Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
X4 Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
X4 Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
X4 Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
X4 Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
X4 Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
X4 Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
X4 Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[X4 Pharmaceuticals Inc：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Genzyme Corp-医療機器分野：企業M&A・提携分析
    Summary Genzyme Corp (Genzyme), a subsidiary of Sanofi, is a biotechnology company that develops specialty treatments targeting rare and special unmet medical needs. Its product pipeline comprises Dupilumab for atopic dermatitis and asthma; Patisiran for familial amyloid polyneuropathy; Isatuximab f …
  • Air Water Inc (4088)：企業の財務・戦略的SWOT分析
    Air Water Inc (4088) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Aptuit LLC-製薬・医療分野：企業M&A・提携分析
    Summary Aptuit LLC (Aptuit) is a provider of drug discovery and development services. The company offer wide range of services such as manufacturing, project management, small and large molecules analysis, formulation development, integrated chemistry, API route scouting and process development, con …
  • Prestige Brands Holdings Inc (PBH)：企業の財務・戦略的SWOT分析
    Prestige Brands Holdings Inc (PBH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Pure Technologies Ltd：企業の戦略的SWOT分析
    Pure Technologies Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Takara Holdings Inc.：企業の戦略・SWOT・財務分析
    Takara Holdings Inc. - Strategy, SWOT and Corporate Finance Report Summary Takara Holdings Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • The Cooper Companies Inc (COO)：企業の財務・戦略的SWOT分析
    The Cooper Companies Inc (COO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • BKW AG (BKW)：電力：M&Aディール及び事業提携情報
    Summary BKW AG (BKW) is an energy and infrastructure company, which plans, builds and operates infrastructure to produce and supply energy. It generates electricity from varied fuel sources such as hydro, nuclear, fossil, and renewable sources primarily, wind and small hydro, besides solar and bioma …
  • Taubman Centers Inc：企業の戦略的SWOT分析
    Taubman Centers Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Nakanishi Inc (7716)：企業の財務・戦略的SWOT分析
    Nakanishi Inc (7716) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Midea Group Co Ltd：企業の戦略・SWOT・財務分析
    Midea Group Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Midea Group Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Alchemia Ltd (ACL)：製薬・医療：M&Aディール及び事業提携情報
    Summary Alchemia Ltd (Alchemia) is an early stage biopharmaceutical company that focuses on the discovery and development of drugs for the treatment of various diseases. It sold the worldwide exclusive intellectual property rights to its product, Fondaparinux sodium (a generic version of the anticoa …
  • Emzor Pharmaceutical Industries Ltd：企業の戦略的SWOT分析
    Emzor Pharmaceutical Industries Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • CeoTronics AG (CEK)：企業の財務・戦略的SWOT分析
    CeoTronics AG (CEK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Infinity Turbine LLC：企業の戦略的SWOT分析
    Infinity Turbine LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Relief Therapeutics Holding AG (RLF)：製薬・医療：M&Aディール及び事業提携情報
    Summary Relief Therapeutics Holding AG (Relief Therapeutics) is a drug development company that offers clinical development of peptides and proteins of natural or engineered origin. The company’s pipeline drug candidates include aviptadil for the treatment of sarcoidosis and low dose interleukin-6 t …
  • The Lion Group：企業の戦略・SWOT・財務情報
    The Lion Group - Strategy, SWOT and Corporate Finance Report Summary The Lion Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Cloud Live Technology Group Co. Ltd.
    Cloud Live Technology Group Co. Ltd. - Strategy, SWOT and Corporate Finance Report Summary Cloud Live Technology Group Co. Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Saudi Kayan Petrochemical Co (2350)：企業の財務・戦略的SWOT分析
    Summary Saudi Kayan Petrochemical Co (Saudi Kayan) is a petrochemical company that manufactures and markets specialty chemicals. The company offers products such as ethanolamines, ethoxylates, phenol, cumene, polycarbonate, ethylene, propylene, polyethylene, monoethanolamine, diethanolamine, trietha …
  • Aramark (ARMK)：企業の財務・戦略的SWOT分析
    Aramark (ARMK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆